Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06830044 · ClinicalTrials.gov registry record · Phase 3

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

A Phase 3 study of Major Depressive Disorder (MDD), sponsored by Vanda Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
500
Enrollment target
20
Study locations

NCT06830044 is a Phase 3 study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 500 participants, above the 136-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (268% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06830044, a Phase 3 study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Vanda Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
500 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder

Conditions Studied

Major Depressive Disorder (MDD)

Interventions

  • DRUG Placebo
  • DRUG Milsaperidone

Study Locations (20)

California

  • Vanda Investigational Site - Garden Grove
  • Vanda Investigational Site - Lemon Grove
  • Vanda Investigational Site - Orange
  • Vanda Investigational Site - San Jose
  • Vanda Investigational Site - Walnut Creek

Florida

  • Vanda Investigational Site - Fort Myers
  • Vanda Investigational Site - Miami
  • Vanda Investigational Site - Miami
  • Vanda Investigational Site - Tampa

New York

  • Vanda Investigational Site - New York
  • Vanda Investigational Site - Staten Island

Texas

  • Vanda Investigational Site - Richardson
  • Vanda Investigational Site - Witchita Falls

Arizona

  • Vanda Investigational Site - Phoenix

Arkansas

  • Vanda Investigational Site - Little Rock

Colorado

  • Vanda Investigational Site - Colorado Springs

Illinois

  • Vanda Investigational Site - Chicago

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-03-03
Est. Completion 2028-03
Phase Phase 3

Sponsor

Vanda Pharmaceuticals

68 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06830044

The ClinicalTrials.gov registry entry for NCT06830044 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 136-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (268% higher). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06830044 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT06830044 about?

NCT06830044 is a clinical study titled "Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder". The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder

What is the current status of trial NCT06830044?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-03-03. Estimated completion is 2028-03.

What conditions does trial NCT06830044 study?

This clinical trial studies the following conditions: Major Depressive Disorder (MDD).

What interventions are being tested in trial NCT06830044?

The interventions under investigation include: Placebo (DRUG), Milsaperidone (DRUG).

Who is sponsoring clinical trial NCT06830044?

This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06830044 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder (MDD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder (MDD)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.